Table 2.
Genes associated with immunotherapy in ovarian cancer.
| Name | Composition | Target point (object) | Potential targets | Role | Source | Ref. |
|---|---|---|---|---|---|---|
| miRNA | miR-222-3p | Macrophages | Diagnostic markers | TAMs M2 polarization | Serum | (15) |
| miR-92a | – | Diagnostic markers | – | Urine | ||
| miR-30a-5p | – | Highly specific diagnostic markers | Inhibits proliferation and metastasis of OC cells | Urine | ||
| miR-let-7 | – | – | Inhibits cell proliferation | OC cell line | ||
| miR-NAs | Between the skin cells | – | Tumor cell spread | OC cells | ||
| miR-330–3p | Mesenchymal ovarian cancer cells | Inhibition of tumor development | Enhanced mesenchymal phenotype | Plasma cells | (142) | |
| miR-21 | Adjacent cancer cell | Diagnosis and treatment of metastatic and recurrent ovarian cancer | Inhibits apoptosis of ovarian cancer cells | CAA/CAF | (129) | |
| miR-233 | EOC cell | Predictors of tumor invasion, metastasis, and recurrence | Induced chemoresistance | Macrophages | (143) | |
| miR-6126 | Tumor cells | Regulates ovarian cancer progression | Tumor suppressor factor | Malignant cells | (144) | |
| IncRNA | UCA1 | Cancer cells | Biomarker | Inhibition of cell metastasis | Urothelial carcinoma | (145) |
| H19 | mRNA | Markers of ovarian cancer development | Apoptosis of OC cells was induced | – | (146) | |
| HOTAIR | LSD 1/REST | Predictive and diagnostic biomarkers | Promotes OC cell proliferation | Plasma | (70) | |
| MALAT1/NEAT2 | miRNA | Potential markers of ovarian cancer metastasis | Promotes cell proliferation, migration, and invasion | – | (147) | |
| MEG3 | pcDNA | Biomarkers for the diagnosis of advanced cancer | Regulation of tumor suppressors | – | (148) | |
| NEAT1 | Tumor cells | Prognostic markers for ovarian cancer | Prediction of patient survival | – | (149) | |
| XIST | Tumor cells | Early diagnosis, potential target of antitumor therapy | Promotes the proliferation and invasion of cancer cells and regulates the carcinogenesis of ovarian cancer | – | (150) | |
| circRNA | CDR1as | miR-135b-5p | Ovarian cancer diagnosis and treatment | Tumor suppressor and promotes the expression of HIF1AN | Ovarian tissue | (151) |
| circKRT7 | miR-29a-3p | Evolutionary driver of malignancy in ovarian cancer | Promotes cancer cell proliferation and metastasis | – | (152) | |
| circPLEKHM3 | miR-9/BRCA 1/KLF 4/AKT 1 | Therapeutic targets, prognostic markers of ovarian cancer | Tumor suppressive effect | – | (153) | |
| cicrCELSR1 | miR-1252 | Promotes ovarian cancer | PTX drug resistance was affected and apoptosis rate was increased | – | (154) | |
| Hsa-circ-0078607 | miR-518a-5p/Fas | Predicting adverse clinical outcomes in ovarian cancer | Inhibits ovarian cancer development | – | (155) | |
| circ-0061140 | miR-361-5p | Ovarian cancer treatment indicators, miRNA sponge | Promotes ovarian cancer development | – | (155) | |
| mRNA | CHAC1 mRNA | Cancer cells | Markers of increased risk of ovarian cancer recurrence | Affects ovarian cancer cell migration | – | (156) |
| MUC16 mRNA | Tumor tissue | Markers of poor prognosis in ovarian cancer | Suggests an abnormal increase in MUC16 | – | (157) | |
| MACC1 mRNA | Tumor tissue | Prognostic markers for ovarian cancer | Affects ovarian cancer migration, invasion and expression | – | (158) | |
| GSK3β mRNA | Tumor cells | Predicts chemotherapy sensitivity | Inhibits the development of ovarian cancer | – | (159) | |
| CEBPA mRNA | Cancer cell cytoplasm | Ovarian cancer diagnosis, evaluation, prognostic markers | Affects the pathogenesis of ovarian cancer | – | (160) |